跨国医疗器械企业布局“中国造”

Group 1 - Major multinational medical device companies are increasingly investing in local production in China, indicating a deepening localization strategy [1] - Illumina, a global leader in gene sequencing, has completed the delivery of its first series of products from its manufacturing base in China, which was established last year [1] - Siemens Healthineers has invested over 1 billion yuan in its Shenzhen production base, with 75% of products sold in China being locally produced in the second quarter of fiscal year 2023 [1] Group 2 - The Chinese medical device industry is experiencing rapid growth, with revenue reaching 1.3 trillion yuan in 2022, making it the second-largest market globally, and an average annual growth rate of 10.54% over the past five years [1] - It is projected that by 2030, China will become the largest medical device market in the world [1] - The competitive landscape is intensifying as both domestic and international companies improve product quality, prompting a focus on localization and supply chain resilience [1] Group 3 - The production capabilities in the Chinese market have significantly improved, facilitating multinational companies in establishing and strengthening local production [2] - Varian Medical established its R&D and production base in Beijing in 2007, initially producing only components due to a lack of local supply chain capabilities [2] - Siemens Healthineers emphasizes the need for skilled and well-educated talent in China, particularly in Shenzhen, which has influenced their decision to invest in new R&D and manufacturing facilities there [2]